Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Vaccines

Free Subscription 24.08.2026 1 BMJ 1 J Gen Virol 1 J Infect Dis 4 J Virol 1 Nat Med 2 Pediatr Infect Dis J 1 PLoS Comput Biol 4 PLoS One 22 Vaccine 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMJ

1. BROWN C
   Why Trump's order to split MMR vaccine is costly and dangerous.
   BMJ. 2026;394:e100632.
   PubMed        
   
   

   
   J Gen Virol

2. SHIM K, Choi JH, Hwang EH, Kim G, et al
   Dose-dependent effects of recombinant spike protein-based vaccination on SARS-CoV-2 evolutionary dynamics and the emergence of variants in hamster models.
   J Gen Virol. 2026;107:002314.
   PubMed         Abstract available
   
   

   
   J Infect Dis

3. ZAMAN K, Bandyopadhyay AS, Gast C, Goswami DR, et al
   Effect of inactivated poliovirus vaccine on nasal mucosal immunity and pharyngeal shedding following novel oral poliovirus vaccine type 2 challenge: A randomized, open-label trial.
   J Infect Dis. 2026 Aug 18:jiag423. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

4. ALVAREZ J, Olczak P, Tsai H-L, Terrell J, et al
   Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36.
   J Virol. 2026 Aug 21:e0044826. doi: 10.1128/jvi.00448.
   PubMed         Abstract available
   
   
5. DWIVEDI S, Kar S, Horton AP, Gollihar JD, et al
   ViralMap: predicting features in viral proteins from primary sequence.
   J Virol. 2026 Jul 28:e0075726. doi: 10.1128/jvi.00757.
   PubMed         Abstract available
   
   
6. PALANDE V, Zhang T, Smith KN, Levinson K, et al
   Exploration of immune correlates of viral clearance after PVX2 immunotherapy in patients with human papillomavirus type 16 infection and cervical intraepithelial neoplasia grade
   J Virol. 2026;100:e0064326.
   PubMed         Abstract available
   
   
7. KING HAD, Subra C, Tourtellott E, Swafford I, et al
   Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.
   J Virol. 2026 Jul 27:e0038926. doi: 10.1128/jvi.00389.
   PubMed         Abstract available
   
   

   
   Nat Med

8. O'LEARY K
   Intercepting pancreatic cancer with a vaccine.
   Nat Med. 2026 Aug 20. doi: 10.1038/d41591-026-00041.
   PubMed        
   
   

   
   Pediatr Infect Dis J

9. PLOTKIN SA
   Cytomegalovirus: A Target for Vaccine Development.
   Pediatr Infect Dis J. 2026 Aug 21. doi: 10.1097/INF.0000000000005341.
   PubMed        
   
   
10. HADDOCK G, Ng M, Johnson T, Vakis A, et al
    Evaluating the Uptake, Safety and Effectiveness of the Maternal RSV Vaccine (RSVpreF) Against Infant Bronchiolitis: Preliminary Real-World Evidence.
    Pediatr Infect Dis J. 2026 Aug 18. doi: 10.1097/INF.0000000000005368.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

11. WANG E, Chakraborty AK
    Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome.
    PLoS Comput Biol. 2026;22:e1014632.
    PubMed         Abstract available
    
    

    
    PLoS One

12. DI CHIARA C, Piche-Renaud PP, Rigamonti V, Cantarutti A, et al
    Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey.
    PLoS One. 2026;21:e0356233.
    PubMed         Abstract available
    
    
13. APONTE-HAO S, Luu H, Martins KJB, Randall JR, et al
    Factors associated with severe COVID-19 outcomes among adults with at least a primary vaccination schedule: A retrospective cohort study from Alberta, Canada.
    PLoS One. 2026;21:e0354822.
    PubMed         Abstract available
    
    
14. D'SOUZA-RUSHTON GC, Seshu U, Blumberger L, Mazhar L, et al
    The CDC's management and COVID-19 vaccine recommendations during the COVID-19 pandemic: A healthcare worker's perspective.
    PLoS One. 2026;21:e0354686.
    PubMed         Abstract available
    
    
15. GELANA N, Abebe F, Tsegaw M, Tadesse Y, et al
    Challenges, opportunities and best practices in routine childhood vaccination services delivery in urban slums and pastoralist regions of Ethiopia: An exploratory qualitative study in marginalized settings.
    PLoS One. 2026;21:e0356253.
    PubMed         Abstract available
    
    

    
    Vaccine

16. THANASI E, McGregor-Harper J, Tramonti Fantozzi MP, Cocco N, et al
    Scaling up vaccination for people living in prisons: a global person-centred need for public health.
    Vaccine. 2026;91:129039.
    PubMed         Abstract available
    
    
17. JAMISON AM, Saiyed S, Gardner LM
    Mandates or "Medical Freedom"? What Florida parents' attitudes suggest about the future of childhood vaccination.
    Vaccine. 2026;91:129060.
    PubMed        
    
    
18. FAHFOUHI Y, Fievez S, Cohen R, Levy C, et al
    A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.
    Vaccine. 2026;91:129036.
    PubMed         Abstract available
    
    
19. WALLACE AS, Sugerman C, Getachew B, Matanock A, et al
    Ethiopia missed opportunities for vaccination study: Cluster-randomized evaluation of 5-dose measles vaccine vials and a flexible open-vial policy, 2021-2022.
    Vaccine. 2026;91:129065.
    PubMed         Abstract available
    
    
20. PAVIA G, Quirino A, Marascio N, Licata F, et al
    Human papillomavirus (HPV) Vaccination programmes across European countries: time-harmonized coverage among adolescent females, socioeconomic predictors, and impact on public interest.
    Vaccine. 2026;91:129058.
    PubMed         Abstract available
    
    
21. DUDLEY MZ, Asif AF, Thomas ES, Lindley MC, et al
    Quality improvement programs for adult immunization: a scoping literature review.
    Vaccine. 2026;89:128878.
    PubMed         Abstract available
    
    
22. JAMROZIK E, Abeler-Dorner L, Chaudhari A, Cheah PY, et al
    Ethical challenges in outbreak trial design: from Ebola to Nipah.
    Vaccine. 2026;89:128858.
    PubMed         Abstract available
    
    
23. GUO Z, Zhao L, Li J, Luo M, et al
    Enhancing secretory expression of CSFV E2 glycoprotein via signal peptide engineering in a recombinant PRRSV vector platform.
    Vaccine. 2026;89:129005.
    PubMed         Abstract available
    
    
24. COLOME-HIDALGO M, Brea J
    Beyond zero-dose: routine immunization retention gaps in the Dominican Republic, 2019-2025.
    Vaccine. 2026;89:129006.
    PubMed         Abstract available
    
    
25. ANGELERI P, Biscayart C, Ferrante D, Macchia A, et al
    Prevalence and determinants of vaccine hesitancy in the City of Buenos Aires, Argentina: A probabilistic household survey.
    Vaccine. 2026;90:129045.
    PubMed         Abstract available
    
    
26. HUIBERTS AJ, Smits MMJ, Hoeve CE, de Melker HE, et al
    Association between post-vaccination adverse events and subsequent COVID-19 booster uptake in the Netherlands.
    Vaccine. 2026;90:129043.
    PubMed         Abstract available
    
    
27. TORAIH EA, Hussein MH, Thomas SJ, Aiash H, et al
    Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals.
    Vaccine. 2026;91:129001.
    PubMed         Abstract available
    
    
28. SUZUKI Y, Arita T, Shirakura M, Kishida N, et al
    A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.
    Vaccine. 2026;91:129048.
    PubMed         Abstract available
    
    
29. DHANDA S, Morris DE, Morton K, Hazell L, et al
    Enhanced passive safety surveillance (EPSS) of a seasonal intranasal influenza vaccine (Fluenz(R) Tetra) in children in England: methodology, results and lessons learned from eight influenza seasons (2015/2016 to 2022/2023).
    Vaccine. 2026;91:129007.
    PubMed         Abstract available
    
    
30. HEIMAN SL, Geiger N
    Overestimation of racial ingroup worry about the COVID-19 vaccine and medical racism.
    Vaccine. 2026;91:129046.
    PubMed         Abstract available
    
    
31. DUTTA S, Ngemera D, Jaillard P, Juneja S, et al
    Lessons learnt from one-year cold chain support for COVID-19 vaccination in 5 middle income countries of North Africa.
    Vaccine. 2026;91:128994.
    PubMed         Abstract available
    
    
32. LENZI J, Montalti M, Di Valerio Z, Frassineti V, et al
    Temporal patterns and potential missed opportunities in pneumococcal vaccination among adults with diabetes: A population-based cohort study.
    Vaccine. 2026;91:129063.
    PubMed         Abstract available
    
    
33. ERBS G, Lybeck K, Jakobsen JT, Nguyen LTM, et al
    Erratum to "Multi-peptide subunit vaccination induced IFN-gamma but lacked efficacy against Mycobacterium avium subsp. paratuberculosis in a goat challenge trial" [Vaccine 88 (2026) 128971].
    Vaccine. 2026 Aug 18:129032. doi: 10.1016/j.vaccine.2026.129032.
    PubMed        
    
    
34. CAMPBELL STATLER M, Bishop-Royse J, Sampson AT, Martin M, et al
    Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data.
    Vaccine. 2026;91:129024.
    PubMed         Abstract available
    
    
35. WANG X, Ji X, Zheng H, Ru M, et al
    AS04-adjuvanted semisynthetic glycoconjugate vaccine against Pseudomonas aeruginosa.
    Vaccine. 2026;91:129066.
    PubMed         Abstract available
    
    
36. SMERTINA E, Rutherford M, Pavy M, Huang N, et al
    Cell culture-derived vaccine for rabbit haemorrhagic disease virus 2.
    Vaccine. 2026;91:129067.
    PubMed         Abstract available
    
    
37. TUOR SM, Matthes KL, Lang P, Fehr J, et al
    Diphtheria in Switzerland, 1877-2022: long-term epidemiology and the impact of mid-20th-century vaccination programs.
    Vaccine. 2026;91:129064.
    PubMed         Abstract available
    
    

    
    Virus Res

38. LEE JY, Choi JA, Jung DI, Park Y, et al
    An inactivated human adenovirus type 55 vaccine attenuates pulmonary pathology in a non-human primate challenge model.
    Virus Res. 2026 Aug 20:199793. doi: 10.1016/j.virusres.2026.199793.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum